Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy
Rubeshan Perumal(South African Medical Research Council), Nesri Padayatchi(Centre for the AIDS Programme of Research in South Africa), Kogieleum Naidoo(Centre for the AIDS Programme of Research in South Africa), Neveen Abdelghani(Centre for the AIDS Programme of Research in South Africa), Nalini Singh(King Edward VIII Hospital), Nonhlanhla Yende‐Zuma(Centre for the AIDS Programme of Research in South Africa), Naressa Naidu(Centre for the AIDS Programme of Research in South Africa), Halima Dawood(Centre for the AIDS Programme of Research in South Africa)
Cited by 16
Related Papers
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
|New England Journal of Medicine|2011|541
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal
|PLoS Medicine|2015|299
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
|American Journal of Respiratory and Critical Care Medicine|2009|266
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis
|International Journal of Epidemiology|2013|204
High Incidence of Hospital Admissions With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Among South African Health Care Workers
|Annals of Internal Medicine|2010|198